0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Clinical Trials Update |

Monoclonal Antibody May Be Helpful for Inflammatory Bowel Disease

Anita Slomski
JAMA. 2013;310(16):1665. doi:10.1001/jama.2013.281199.
Text Size: A A A
Published online

Extract

Vedolizumab, a humanized monoclonal antibody that inhibits leukocyte trafficking to the gut mucosa, was more effective than placebo in treating patients with moderate to severe active ulcerative colitis and Crohn disease, according to results of 2 separate phase 3 trials involving 2010 patients (Feagan BG et al. N Engl J Med. 2013;369[8]:699-710; Sandborn WJ et al. N Engl J Med. 2013;369[8]:711-721).

Each of the 2 trials, funded by Millennium Pharmaceuticals, had an induction-therapy phase, during which patients were randomly assigned to receive vedolizumab or placebo. Those who had a clinical response at 6 weeks were enrolled in the 52-week maintenance-therapy phase, during which they were randomly assigned to receive vedolizumab every 8 weeks, vedolizumab every 4 weeks, or placebo.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com
brightcove.createExperiences();